46results about How to "Passive targeting" patented technology

The invention discloses a preparation method for hypericin albumin nanometer particles, which comprises (1) using bovine serum albumin as a carrier material to be dissolved in distilled water to manufacture carrier solution with the mass concentration of 10% to 40%; (2) dissolving hypericin in ethanol with the concentration more than 95% to produce oil phase with the mass concentration of 20% to 40%; (3) adding the oil phase having been fully stirred into the carrier solution, adjusting potential of hydrogen (PH) to 9, dropwise adding emulsifier to fully emulsify, then dropping glutaraldehyde to cure for more than 24 hours, and obtaining curing nanometer particle solution; (4) centrifuging at high speed of 15,000 rpm / min to 20,000 rpm / min, removing supernate, adding distilled water to perform ultrasonic dispersion, centrifuging again at high speed, removing supernate, washing with water and collecting, and drying in vacuum or freezing mode to achieve hypericin albumin nanometer particles. The hypericin albumin nanometer particles prepared with the method are good in stability on light and heat, and effective content of hypericin is improved.

The invention relates to a liposome drug combination and a preparation method of the drug combination. The weights of the effective drug components are listed as follows: the weight of the admixture for hydrogenated soybean phosphatide and sheep brain lecithin with a weight ratio of 2:1 is 300 to 550; the weight of the admixture for cholesterol, stearamide and beta-sitosterol with a weight ratio of 1:1:0.1 is 200 to 400; the weight of the admixture for tiopronin and vitamin E with a weight ratio of 4:1 is 100 to 200; the weight of the admixture for polyethylene glycol-4000 and polyethylene glycol-6000 with a discretional weight ratio is 150 to 200; the weight of vitamin C is 150 to 180; the weight of the admixture for tert-butyl alcohol and anhydrous alcohol with a weight ratio of 1.5 to 2.2:0.01 to 0.05 is 4000 to 7000; the weight of the admixture for paclitaxel and polyene paclitaxel with a discretional weight ratio is 20 and 40; the weight of the admixture for diphenhydramine and cimetidine with a weight ratio of 1:6 is 350 to 500. The invention has the advantages of reducing the drug dosage by nearly one time, increasing the curative effect by over 15 percent, and greatly reducing the side effect of the drugs.

The invention discloses a cabazitaxel oligo / polylactic acid coupled prodrug and a preparation method thereof. The preparation method is characterized in that cabazitaxel and oligo / polylactic acid undergo an esterification reaction under the action of a condensing agent and a catalyst to obtain the cabazitaxel oligo / polylactic acid coupled prodrug. The invention also discloses a cabazitaxel-oligo / polylactic acid coupled prodrug preparation, and a preparation method and an application thereof. The oligo / polylactic acid is covalently coupled with cabazitaxel, so the in vivo release rate of cabazitaxel is can be regulated, the precipitation of cabazitaxel, caused by strong release, is prevented, the in vivo cycle period of the cabazitaxel is prolonged, and the maximum tolerable dose is increased. The oligo / polylactic acid is approved for use by the US FDA and has an excellent application prospect. The cabazitaxel oligo / polylactic acid prodrug and an amphiphilic polymer PEG5k-PLA8k are assembled to form nanoparticles, and the nanoparticles have a passive targeting effect, and are easily retained in the tumor site by the EPR effect in order to greatly reduce the toxic and side effects ofthe drug on normal tissues.

The invention discloses a preparation method of CPZ-coupled MS2 protein nanoparticles and an application thereof in breast cancer resistance. The CPZ is coupled on the surface of MS2 protein nanoparticles by covalent coupling, so that the MS2 protein nanoparticles have the characteristics of good water solubility, high drug loading rate, uniformity and stability. Hydrophobicity of phthalocyanine compounds leads to aggregation of the compounds in physiological environment, which affects photophysical (reduced 1O2 formation), chemical (reduced solubility) and biological (insufficient tumor localization) properties of the compounds and reduces the photodynamic therapy (PDT) efficacy of the compounds. Through the nano covalent coupling, the drug effect of ZnPc on breast cancer is improved, nanoparticles can obviously improve the solubility of monocarboxylic groups, provide appropriate particle size and surface properties, and prolong blood circulation, thereby allowing selective accumulation of tumors through enhanced permeability and retention effect (EPR), so that the nanoparticles have a good effect in the application of breast cancer.

The invention provides a targeted photosensitizer and a preparation method and application thereof, and an anti-tumor drug comprising the targeted photosensitizer, and relates to the field of photosensitizers. The targeted photosensitizer takes folic acid as a tumor target group; a photoactive effector molecule and the folic acid are connected through a carbonate ester bond, a disulfide bond and apeptide chain in sequence; after the targeted photosensitizer enters a tumor cell, the photoactive effector molecule is released through exchange reaction of sulfydryl and the disulfide bond and molecular nucleophilic substitution reaction in a strong reductive environment, so as to exert an effect of photodynamically killing a tumor under the illumination. The preparation method of the targetedphotosensitizer comprises simple steps and is easy to operate; furthermore, no large-sized or complicated instruments are needed, and the preparation method is suitable for expanding large-scale production and preparation.

The invention discloses a single-drug self-assembly of a molecular-targeted drug, a co-assembled nanometer drug of a molecular-targeted drug and other hydrophobic drugs, a preparation method and an application thereof. At the same time, the drugs used have been approved by the US FDA for marketing, and have good application prospects. Molecular targeted drug single-drug self-assembly, molecular targeted drug and hydrophobic drug multi-drug co-assembly to form nanoparticles, without additional carrier, has passive targeting effect, and is easy to stay in the tumor site through the EPR effect, thereby greatly reducing drug interaction. Toxic side effects of normal tissues.